MediWound Ltd. (NASDAQ:MDWD) Short Interest Up 20.9% in January

MediWound Ltd. (NASDAQ:MDWD) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,284,063 shares, an increase of 20.9% from the January 15th total of 1,062,079 shares. Based on an average daily volume of 150,032 shares, the short-interest ratio is presently 8.6 days. Approximately 11.0% of the company’s shares are sold short. Approximately 11.0% of the company’s shares are sold short. Based on an average daily volume of 150,032 shares, the short-interest ratio is presently 8.6 days.

MediWound Price Performance

NASDAQ MDWD traded up $0.50 during trading on Tuesday, hitting $17.77. The company’s stock had a trading volume of 30,063 shares, compared to its average volume of 114,048. The company has a market cap of $228.13 million, a PE ratio of -9.35 and a beta of 0.13. The business’s 50 day simple moving average is $18.08 and its 200-day simple moving average is $17.95. MediWound has a fifty-two week low of $14.14 and a fifty-two week high of $22.50.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.57. The business had revenue of $5.43 million for the quarter, compared to the consensus estimate of $6.56 million. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%. Analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Wall Street Zen upgraded shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 target price (up previously from $31.00) on shares of MediWound in a research note on Friday, November 21st. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.50.

Institutional Trading of MediWound

Hedge funds and other institutional investors have recently modified their holdings of the company. Rosalind Advisors Inc. raised its stake in shares of MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after purchasing an additional 341,993 shares during the period. Kotler Kevin bought a new position in shares of MediWound in the fourth quarter worth $6,225,000. Meitav Investment House Ltd. lifted its position in shares of MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after buying an additional 260,116 shares during the last quarter. Millennium Management LLC lifted its stake in shares of MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after acquiring an additional 136,884 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after purchasing an additional 68,756 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.